Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says

Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet